吉利德与瑞典生物技术公司达成价值4亿美元的生物技术交易，涉及其TREX1癌症项目。

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks.